866-997-4948(US-Canada Toll Free)

Zicronapine Analysis and Forecasts from 2014 to 2020

Published By :

GlobalData

Published Date : Jul 2011

Category :

Therapeutic Area

No. of Pages : 28 Pages


GlobalDatas pharmaceuticals report, Zicronapine Analysis and Forecasts from 2014 to 2020 provides Zicronapine sales estimates for US and EU5. In addition, it covers detailed clinical assessment of the drug, factors impacting drug sales, competitive landscape, and analysis of sales performance during the forecast period (2014-2020). The report also includes information on Schizophrenia market. This report is built using data and information sourced from GlobalDatas proprietary databases, primary and secondary research using Companys corporate website, SEC filings, investor presentations and featured press releases, both from company and industry-specific third party sources, put together with in-house analysis, by GlobalData's team of industry experts. 

Scope
  • Therapy area profile including patient population for the US, EU5 and Japan (seven major markets)
  • Analysis and review of Zicronapine including sales data
  • Qualitative and quantitative assessment of market space
  • Analysis of the trends, drivers and restraints shaping and defining the markets
  • In-depth analysis of Zicronapine including efficacy, safety, pricing and other details which influence its sales potential
  • Detailed sales forecast for 2014-2020 for Zicronapine in the US and EU5
Reasons to buy
  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of competition by understanding the changing competitive landscape
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of the drugs performance 
  • Examine the historical sales performance of a drug in seven major markets
  • Obtain sales forecast for currently marketed/pipeline drug for 2011-2020 for all seven major markets
Table of Content

1 Table of Contents
1 Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3

2 Introduction 4
2.1 Schizophrenia 4
2.2 Symptoms 4
2.3 Schizophrenia Market 4
2.4 Epidemiology 4
2.5 Etiology 5
2.5.1 Genetic Factors 5
2.5.2 Environmental Factors 5
2.5.3 Abnormal Brain Structure 6
2.6 GlobalData Report Guidance 6

3 Schizophrenia: Market Characterization 7
3.1 Schizophrenia Market 7
3.2 Schizophrenia Market Forecasts and CAGR 7
3.3 Drivers of Schizophrenia Therapeutics Market 8
3.3.1 Patent Expiry of Leading Marketed Drugs 8
3.3.2 Increasing Patient Pool 8
3.3.3 High Prescription Rates 8
3.3.4 Low Patient Compliance Rate 8
3.3.5 High Unmet Need 8

4 Classification of Schizophrenia 9
4.1 Age of Onset of Schizophrenia 9
4.1.1 Pediatric / Adolescent / Childhood Schizophrenia 9
4.1.2 Adult Schizophrenia 10
4.2 Associated Symptoms 10
4.2.1 Paranoid Schizophrenia 10
4.2.2 Disorganized Schizophrenia 10
4.2.3 Catatonic Schizophrenia 10
4.2.4 Residual Schizophrenia 10
4.2.5 Undifferentiated Disorder 10

5 Treatment for Schizophrenia 11
5.1 Crisis Resolution Teams (CRT) 11
5.2 Voluntary and Compulsory Detention 11
5.3 Antipsychotics 11
5.3.1 Typical Antipsychotics 11
5.3.2 Atypical Antipsychotics 12
5.3.3 Increased Mortality in Elderly Patients with Dementia-Related Psychosis 12

6 Zicronapine 13
6.1 Introduction 13
6.2 Mechanism of Action 13
6.3 Clinical Studies 13
6.4 Zicronapine Drug Development Status 13
6.5 Factors Affecting Sales of Zicronapine 14
6.5.1 Multi Receptorial Profile 14
6.5.2 Affinity to Monaminergic Receptors 14
6.5.3 High Competition 14
6.5.4 Lack of Presence in Japan 14
6.5.5 Me too Drug 14
6.6 Intensity of Competition 15
6.7 Sales Forecasts 15
6.7.1 Target Patient Pool of Zicronapine 15
6.7.2 Dosing 15
6.7.3 Market Penetration 15
6.7.4 Annual Cost of Therapy 16
6.7.5 Sales Projections of Zicronapine 17

7 Schizophrenia Market: Appendix 25
7.1 Market Definitions 25
7.2 Abbreviations 25
7.3 Research Methodology 25
7.4 Drug Sales Estimates Model 27
7.5 Contact Us 28
7.6 Disclaimer 28
7.7 Sources 28

List of Table


Table 1: Zicronapine, Drug Development Status, 2011 14
Table 2: Zicronapine, Annual Treatment Costs, 2014 16
Table 3: Zicronapine, Schizophrenia, Global, Sales Forecasts ($m), 20142020 17
Table 4: Zicronapine, Schizophrenia, The US, Sales Forecasts ($m), 20162020 18
Table 5: Zicronapine, Schizophrenia, UK, Sales Forecasts ($m), 20142020 19
Table 6: Zicronapine, Schizophrenia, France, Sales Forecasts ($m), 20142020 20
Table 7: Zicronapine, Schizophrenia, Germany, Sales Forecasts ($m), 20142020 21
Table 8: Zicronapine, Schizophrenia, Italy, Sales Forecasts ($m), 20142020 22
Table 9: Zicronapine, Schizophrenia, Spain, Sales Forecasts ($m), 20142020 23

List of Chart


Figure 1: Risk of Developing Schizophrenia 5
Figure 2: Environmental Factors in the Development of Schizophrenia 6
Figure 3: Schizophrenia, Global, Market Size Forecasts ($ billion), 20102020 7
Figure 4: Classification of Schizophrenia based on the Age of Disease Onset 9
Figure 5: Drug Model Diagram of Zicronapine 15
Figure 6: Zicronapine, Schizophrenia, Global, Sales Forecasts ($m), 20142020 17
Figure 7: Zicronapine, Schizophrenia, The US, Sales Forecasts ($m), 20162020 18
Figure 8: Zicronapine, Schizophrenia, UK, Sales Forecasts ($m), 20142020 19
Figure 9: Zicronapine, Schizophrenia, France, Sales Forecasts ($m), 20142020 20
Figure 10: Zicronapine, Schizophrenia, Germany, Sales Forecasts ($m), 20142020 21
Figure 11: Zicronapine, Schizophrenia, Italy, Sales Forecasts ($m), 20142020 22
Figure 12: Zicronapine, Schizophrenia, Spain, Sales Forecasts ($m), 20142020 23
Figure 13: Zicronapine, Schizophrenia, Global, Sales Distribution by Country (%), 2020 24

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *